Related Experiment Videos
[Endothelial dysfunction in peripheral arterial occlusive disease: from basic research to clinical use]
1Institut für Klinische Pharmakologie, Medizinische Hochschule Hannover.
VASA. Zeitschrift Fur Gefasskrankheiten
|August 1, 1997
Summary
Patients with peripheral arterial occlusive disease (PAOD) show impaired nitric oxide (NO) formation. This may be due to increased asymmetrical dimethylarginine (ADMA), an inhibitor of NO synthesis, impacting vascular health.
Area of Science:
- Cardiovascular Science
- Vascular Biology
- Biochemistry
Background:
- Nitric oxide (NO) has multiple anti-atherosclerotic effects in the vascular wall, including vasodilation and inhibition of platelet aggregation.
- Biological functions of NO are often impaired in patients with peripheral arterial occlusive disease (PAOD).
Purpose of the Study:
- To investigate impaired NO formation in PAOD patients.
- To explore the role of asymmetrical dimethylarginine (ADMA) in the pathophysiology of PAOD.
- To highlight the clinical significance of NO-mediated endothelial functions.
Main Methods:
- Cross-over study involving 77 PAOD patients.
- Measurement of NO index metabolites: nitrate and cyclic guanosine monophosphate (cGMP).
- Assessment of asymmetrical dimethylarginine (ADMA) levels.
Main Results:
- Demonstrated impaired NO formation in PAOD patients.
- Identified potential link between ADMA accumulation and impaired NO synthesis.
- Indicated that endothelial NO functions are crucial for cardiovascular disease risk assessment and therapeutic strategies.
Conclusions:
- Impaired NO formation is a feature of PAOD, potentially linked to elevated ADMA.
- Endothelium-dependent vasodilation measurement could serve as a diagnostic risk indicator.
- Therapeutic strategies targeting endothelial function, such as L-arginine administration, show future promise.